The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.

Changes in serum LRG levels relates with the prognosis in primary biliary cholangitis

Sep 6th 2019

Hayashi M et al, Department of Gastroenterology, Fukushima Medical University School of Medicine, retrospectively reviewed clinical data of 129 individuals with biopsy-confirmed primary biliary cholangitis (PBC). 

Leucine-rich α2 glycoprotein (LRG) was analyzed by enzyme-linked immunosorbent assay (ELISA) using stored sera at biopsy (n = 129) and after treatment (n = 80) and compared with biochemical test results, histological observations, and the development of cirrhosis-related conditions.

This revealed that serum LRG level of PBC was 1) higher than age matched healthy controls, 2) levels of LRG significantly decreased (55.8 μg/mL vs. 39.8 μg/mL, P < 0.001) after ursodeoxycholic acid (UDCA) treatment, 3) and Delta-LRG (the difference of LRG levels before and after UDCA treatment) was associated with the development of cirrhosis-related conditions independently with histological observations.

Changes in serum levels of leucine-rich α2-glycoprotein predict prognosis in primary biliary cholangitis. Hayashi M et al. Hepatol Res. 2018 Nov 24.

This report revealed the usefulness to assess serum LRG change to predict the prognosis of PBC after treatment.

In this report our company’s #27769 Human LRG Assay Kit – IBL is used to measure human serum samples. This assay is for research use only and not for diagnostic purposes.